Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B-Non Hodgkin Lymphoma (B-NHL) Who Are Ineligible to Autologous Stem Cell Transplantation

NCT04531046 is registered in ClinicalTrials.gov with The Lymphoma Academic Research Organisation as lead sponsor.

NCT NCT04531046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04531046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B-Non Hodgkin Lymphoma (B-NHL) Who Are Ineligible to Autologous Stem Cell Transplantation
Lead sponsor
The Lymphoma Academic Research Organisation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 10, 2021
Completion date
June 30, 2026
Enrollment
62 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma recurrent, b-cell lymphoma refractory